Glioblastoma Multiforme and its Cell Interruption

Author(s): Sankha Bhattacharya*

Journal Name: Current Cancer Therapy Reviews

Volume 17 , Issue 2 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Glioblastoma (GBM) is a fatal type of brain cancer or primary glial neoplasm, mostly targeting aged populations. The average survival is only 15 months from the date of occurrence. It is often observed that, the invasive nature of the tumour is the main reason for poor prognosis and strong recurrence of GBM in patients even after prescribed treatments. Despite all types of therapies, it is necessary to understand the various molecular mechanisms and signalling pathways to identify targets for GBM treatment. This compilation is specifically designed to discuss Wnt signalling and Hedgehog-GLI1 pathways, which have positive and negative regulation against GBM. The recent research finding associated with different signalling pathways for GBM has also been discussed within this article.

Keywords: Glioblastoma multiforme (GBM), wnt signalling, hedgehog-gLI1, rho/rhzo kinase (ROCK), β-catenin, neoplasm.Glioblastoma multiforme (GBM), wnt signalling, hedgehog-gLI1, rho/rhzo kinase (ROCK), β-catenin, neoplasm.

[1]
Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 2006; 12(18): 5288-97.
[http://dx.doi.org/10.1158/1078-0432.CCR-06-0438] [PMID: 17000661]
[2]
Stegh AH, Chin L, Louis DN, DePinho RA. What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator. Cell Cycle 2008; 7(18): 2833-9.
[http://dx.doi.org/10.4161/cc.7.18.6759] [PMID: 18769159]
[3]
Wolinsky JB, Colson YL, Grinstaff MW. Local drug delivery strategies for cancer treatment: Gels, nanoparticles, polymeric films, rods, and wafers. J Control Release 2012; 159(1): 14-26.
[http://dx.doi.org/10.1016/j.jconrel.2011.11.031] [PMID: 22154931]
[4]
Tait MJ, Petrik V, Loosemore A, Bell BA, Papadopoulos MC. Survival of patients with glioblastoma multiforme has not improved between 1993 and 2004: Analysis of 625 cases. Br J Neurosurg 2007; 21(5): 496-500.
[http://dx.doi.org/10.1080/02688690701449251] [PMID: 17852105]
[5]
Pruszak J. Neural surface antigens: From basic biology towards biomedical applications. USA: Academic Press 2015.
[6]
Bodduluru LN, Kasala ER, Thota N, Barua CC, Sistla R. Chemopreventive and therapeutic effects of nimbolide in cancer: The underlying mechanisms. Toxicol In Vitro 2014; 28(5): 1026-35.
[http://dx.doi.org/10.1016/j.tiv.2014.04.011] [PMID: 24759803]
[7]
Amaravadi RK, Lippincott-Schwartz J, Yin X-M, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 2011; 17(4): 654-66.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-2634] [PMID: 21325294]
[8]
Zong H, Parada LF, Baker SJ. Cell of origin for malignant gliomas and its implication in therapeutic development. Cold Spring Harb Perspect Biol 2015; 7(5): a020610.
[http://dx.doi.org/10.1101/cshperspect.a020610] [PMID: 25635044]
[9]
Ylivinkka I. Netrins in glioma biology: Regulators of tumor cell proliferation, motility and stemness. University of Helsinki 2017.
[10]
Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion.Seminars in cancer biology. Elsevier 2010; Vol. 3: pp. 161-8.
[http://dx.doi.org/10.1016/j.semcancer.2010.05.002]
[11]
Mayes DA, Hu Y, Teng Y, et al. PAX6 suppresses the invasiveness of glioblastoma cells and the expression of the matrix metalloproteinase-2 gene. Cancer Res 2006; 66(20): 9809-17.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-3877] [PMID: 17047041]
[12]
De Wever O, Pauwels P, De Craene B, et al. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol 2008; 130(3): 481-94.
[http://dx.doi.org/10.1007/s00418-008-0464-1] [PMID: 18648847]
[13]
Roslan Z, Muhamad M, Selvaratnam L, Ab-Rahim S. The roles of low-density lipoprotein receptor-related proteins 5, 6, and 8 in cancer: A review. J Oncol 2019; 2019: 4536302.
[http://dx.doi.org/10.1155/2019/4536302] [PMID: 31031810]
[14]
Rheinbay E, Suvà ML, Gillespie SM, et al. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep 2013; 3(5): 1567-79.
[http://dx.doi.org/10.1016/j.celrep.2013.04.021] [PMID: 23707066]
[15]
Paw I, Carpenter RC, Watabe K, Debinski W, Lo H-W. Mechanisms regulating glioma invasion. Cancer Lett 2015; 362(1): 1-7.
[http://dx.doi.org/10.1016/j.canlet.2015.03.015] [PMID: 25796440]
[16]
Scales SJ, de Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009; 30(6): 303-12.
[http://dx.doi.org/10.1016/j.tips.2009.03.007] [PMID: 19443052]
[17]
Uchida H, Arita K, Yunoue S, et al. Role of sonic hedgehog signaling in migration of cell lines established from CD133-positive malignant glioma cells. J Neurooncol 2011; 104(3): 697-704.
[http://dx.doi.org/10.1007/s11060-011-0552-2] [PMID: 21380601]
[18]
Zang J, Zheng MH, Cao XL, et al. Adenovirus infection promotes the formation of glioma stem cells from glioblastoma cells through the TLR9/NEAT1/STAT3 pathway. Cell Commun Signal 2020; 18(1): 135.
[http://dx.doi.org/10.1186/s12964-020-00598-7] [PMID: 32843056]
[19]
He Y, Roos WP, Wu Q, Hofmann TG, Kaina B. The SIAH1-HIPK2-p53ser46 damage response pathway is involved in temozolomide-induced glioblastoma cell death. Mol Cancer Res 2019; 17(5): 1129-41.
[http://dx.doi.org/10.1158/1541-7786.MCR-18-1306] [PMID: 30796178]
[20]
Nanta R, Shrivastava A, Sharma J, Shankar S, Srivastava RK. Inhibition of sonic hedgehog and PI3K/Akt/mTOR pathways cooperate in suppressing survival, self-renewal and tumorigenic potential of glioblastoma-initiating cells. Mol Cell Biochem 2019; 454(1-2): 11-23.
[http://dx.doi.org/10.1007/s11010-018-3448-z] [PMID: 30251117]
[21]
Bianco J, Bastiancich C, Jankovski A, des Rieux A, Préat V, Danhier F. On glioblastoma and the search for a cure: Where do we stand? Cell Mol Life Sci 2017; 74(13): 2451-66.
[http://dx.doi.org/10.1007/s00018-017-2483-3] [PMID: 28210785]
[22]
Clow B. Who’s afraid of Susan Sontag? Or, the myths and metaphors of cancer reconsidered. Soc Hist Med 2001; 14(2): 293-312.
[http://dx.doi.org/10.1093/shm/14.2.293] [PMID: 11697354]
[23]
Lan X, Jörg DJ, Cavalli FMG, et al. Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. Nature 2017; 549(7671): 227-32.
[http://dx.doi.org/10.1038/nature23666] [PMID: 28854171]
[24]
Hui AB-Y, Lo K-W, Yin X-L, Poon W-S, Ng H-K. Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest 2001; 81(5): 717-23.
[http://dx.doi.org/10.1038/labinvest.3780280] [PMID: 11351043]
[25]
Figueroa JM, Skog J, Akers J, et al. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro-oncol 2017; 19(11): 1494-502.
[http://dx.doi.org/10.1093/neuonc/nox085] [PMID: 28453784]
[26]
Grosios K, Traxler P. Tyrosine kinase targets in drug discovery. Drugs Future 2003; 28(7): 226-9.
[http://dx.doi.org/10.1358/dof.2003.028.07.857184]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 2
Year: 2021
Published on: 07 October, 2020
Page: [89 - 92]
Pages: 4
DOI: 10.2174/1573394716999201007125709

Article Metrics

PDF: 137
HTML: 2